COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA. 2 subvariants - surveillance results from southern Sweden, December 2021 to March 2022

被引：39

作者：

Bjork, Jonas ^{[1
,2
]}

Bonander, Carl ^{[3
]}

Moghaddassi, Mahnaz ^{[4
]}

Rasmussen, Magnus ^{[5
]}

Malmqvist, Ulf ^{[2
]}

Inghammar, Malin ^{[5
]}

Kahn, Fredrik ^{[5
]}

机构：

[1] Skane Univ Hosp, Clin Studies Sweden, Lund, Sweden

[2] Lund Univ, Div Occupat & Environm Med, Lund, Sweden

[3] Univ Gothenburg, Sch Publ Hlth & Community Med, Inst Med, Gothenburg, Sweden

[4] Lund Univ, Dept Clin Sci Malmo, Social Med & Global Hlth, Malmo, Sweden

[5] Lund Univ, Skane Univ Hosp, Dept Clin Sci Lund, Sect Infect Med, Lund, Sweden

来源：

EUROSURVEILLANCE | 2022年 / 27卷 / 18期

基金：

瑞典研究理事会;

关键词：

D O I：

10.2807/1560-7917.ES.2022.27.18.2200322

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

We compared vaccine effectiveness against severe COVID-19 between December 2021 and March 2022 when Omicron BA.1 and BA.2 were the dominating SARS-CoV-2 variants in Scania county, Sweden. Effectiveness remained above 80% after the transition from BA.1 to BA.2 among people with at least three vaccine doses but the point estimate decreased markedly to 54% among those with only two doses. Protection from prior infection was also lower after the transition to BA. 2. Booster vaccination seems necessary to maintain sufficient protection.

引用

页码：8 / 13

页数：6

共 10 条

[1]

Altarawneh H.N., 2022, EFFECT PRIOR INFECTI, DOI 10.1101/2022.03.22.22272745

[2] High level of protection against COVID-19 after two doses of BNT162b2 vaccine in the working age population - first results from a cohort study in Southern Sweden [J].

Bjork, Jonas ;

Inghammar, Malin ;

Moghaddassi, Mahnaz ;

Rasmussen, Magnus ;

Malmqvist, Ulf ;

Kahn, Fredrik .

INFECTIOUS DISEASES, 2022, 54 (02) :128-133

[3]

Chemaitelly H, 2022, medRxiv, DOI [10.1101/2022.02.24.22271440, 10.1101/2022.02.24.22271440, DOI 10.1101/2022.02.24.22271440]

[4] RE: "MEASUREMENT OF VACCINE DIRECT EFFECTS UNDER THE TEST-NEGATIVE DESIGN" [J].

Dean, Natalie E. .

AMERICAN JOURNAL OF EPIDEMIOLOGY, 2019, 188 (04) :806-807

[5]

Eales O., 2022, PREPRINT, DOI [10.1101/2022.03.29.22273042, DOI 10.1101/2022.03.29.22273042]

[6]

Inghammar M, 2021, MEDRXIV, DOI [10.1101/2021.08.12.21261981, DOI 10.1101/2021.08.12.21261981]

[7] Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities- surveillance results from southern Sweden, July 2021 to January 2022 [J].

Kahn, Fredrik ;

Bonander, Carl ;

Moghaddassi, Mahnaz ;

Rasmussen, Magnus ;

Malmqvist, Ulf ;

Inghammar, Malin ;

Bjork, Jonas .

EUROSURVEILLANCE, 2022, 27 (09)

[8]

Kirsebom F. C. M., 2022, MEDRXIV, DOI [10.1101/2022.03.22.22272691, DOI 10.1101/2022.03.22.22272691]

[9]

Lyngse F.P., 2022, medRxiv, DOI DOI 10.1101/2022.01.28.22270044

[10] Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden [J].

Nordstrom, Peter ;

Ballin, Marcel ;

Nordstrom, Anna .

LANCET INFECTIOUS DISEASES, 2022, 22 (06) :781-790

← 1 →